BR112019010331A2 - composição farmacêutica para evitar a dependência de opioides - Google Patents
composição farmacêutica para evitar a dependência de opioidesInfo
- Publication number
- BR112019010331A2 BR112019010331A2 BR112019010331-7A BR112019010331A BR112019010331A2 BR 112019010331 A2 BR112019010331 A2 BR 112019010331A2 BR 112019010331 A BR112019010331 A BR 112019010331A BR 112019010331 A2 BR112019010331 A2 BR 112019010331A2
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- pharmaceutical composition
- opioid dependence
- prevent opioid
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662427365P | 2016-11-29 | 2016-11-29 | |
| US62/427,365 | 2016-11-29 | ||
| PCT/US2017/063417 WO2018102294A1 (en) | 2016-11-29 | 2017-11-28 | A pharmaceutical composition for averting opioid addiction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019010331A2 true BR112019010331A2 (pt) | 2019-10-22 |
Family
ID=60766150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019010331-7A BR112019010331A2 (pt) | 2016-11-29 | 2017-11-28 | composição farmacêutica para evitar a dependência de opioides |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10736961B2 (enExample) |
| EP (1) | EP3548082B1 (enExample) |
| JP (1) | JP7071975B2 (enExample) |
| KR (1) | KR20190090820A (enExample) |
| CN (1) | CN110072549A (enExample) |
| AU (1) | AU2017366870B2 (enExample) |
| BR (1) | BR112019010331A2 (enExample) |
| CA (1) | CA3045116A1 (enExample) |
| CL (1) | CL2019001385A1 (enExample) |
| CO (1) | CO2019005247A2 (enExample) |
| EA (1) | EA201991283A9 (enExample) |
| IL (1) | IL266640B (enExample) |
| MA (2) | MA46951A (enExample) |
| MX (1) | MX2019006013A (enExample) |
| MY (1) | MY200701A (enExample) |
| PH (1) | PH12019501087A1 (enExample) |
| WO (1) | WO2018102294A1 (enExample) |
| ZA (1) | ZA201902967B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3108697A1 (en) * | 2018-08-10 | 2020-02-13 | Regeneron Pharmaceuticals, Inc. | A pharmaceutical composition for safe and effective treatment of knee and/or hip pain |
| US20250011408A1 (en) | 2021-11-19 | 2025-01-09 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for reducing centralized pain |
| WO2023212586A1 (en) | 2022-04-27 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Methods for selecting patients for treatment with an ngf antagonist |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP2270048B1 (en) | 2002-12-24 | 2015-11-11 | Rinat Neuroscience Corp. | Anti-NGF antibodies and methods using same |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| ME00226B (me) | 2004-07-15 | 2011-02-10 | Medarex Llc | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade |
| NZ587107A (en) | 2006-06-02 | 2012-05-25 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| MY161564A (en) * | 2007-08-10 | 2017-04-28 | Regeneron Pharma | High affinity human antibodies to human nerve growth factor |
| CN106267189B (zh) | 2010-10-06 | 2021-02-26 | 瑞泽恩制药公司 | 含有抗白介素-4受体(il-4r)的抗体的稳定制剂 |
-
2017
- 2017-11-28 KR KR1020197018394A patent/KR20190090820A/ko not_active Ceased
- 2017-11-28 AU AU2017366870A patent/AU2017366870B2/en active Active
- 2017-11-28 IL IL266640A patent/IL266640B/en unknown
- 2017-11-28 CA CA3045116A patent/CA3045116A1/en active Pending
- 2017-11-28 MY MYPI2019002915A patent/MY200701A/en unknown
- 2017-11-28 CN CN201780073865.2A patent/CN110072549A/zh active Pending
- 2017-11-28 MA MA046951A patent/MA46951A/fr unknown
- 2017-11-28 MX MX2019006013A patent/MX2019006013A/es unknown
- 2017-11-28 BR BR112019010331-7A patent/BR112019010331A2/pt unknown
- 2017-11-28 WO PCT/US2017/063417 patent/WO2018102294A1/en not_active Ceased
- 2017-11-28 US US15/824,106 patent/US10736961B2/en active Active
- 2017-11-28 EP EP17817965.1A patent/EP3548082B1/en active Active
- 2017-11-28 JP JP2019525911A patent/JP7071975B2/ja active Active
- 2017-11-28 MA MA45890A patent/MA45890B2/fr unknown
- 2017-11-28 EA EA201991283A patent/EA201991283A9/ru unknown
-
2019
- 2019-05-13 ZA ZA2019/02967A patent/ZA201902967B/en unknown
- 2019-05-16 PH PH12019501087A patent/PH12019501087A1/en unknown
- 2019-05-22 CO CONC2019/0005247A patent/CO2019005247A2/es unknown
- 2019-05-22 CL CL2019001385A patent/CL2019001385A1/es unknown
-
2020
- 2020-07-02 US US16/920,178 patent/US11491222B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CL2019001385A1 (es) | 2019-07-26 |
| ZA201902967B (en) | 2024-10-30 |
| US10736961B2 (en) | 2020-08-11 |
| KR20190090820A (ko) | 2019-08-02 |
| US11491222B2 (en) | 2022-11-08 |
| JP2019535716A (ja) | 2019-12-12 |
| EA201991283A9 (ru) | 2019-11-27 |
| EA201991283A1 (ru) | 2019-09-30 |
| IL266640A (en) | 2019-07-31 |
| MA46951A (fr) | 2019-10-09 |
| AU2017366870B2 (en) | 2024-09-19 |
| CA3045116A1 (en) | 2018-06-07 |
| MA45890A1 (fr) | 2020-02-28 |
| WO2018102294A1 (en) | 2018-06-07 |
| CN110072549A (zh) | 2019-07-30 |
| AU2017366870A1 (en) | 2019-06-06 |
| JP7071975B2 (ja) | 2022-05-19 |
| PH12019501087A1 (en) | 2019-08-19 |
| US20180147280A1 (en) | 2018-05-31 |
| MX2019006013A (es) | 2019-10-14 |
| IL266640B (en) | 2022-09-01 |
| EP3548082B1 (en) | 2024-05-15 |
| CO2019005247A2 (es) | 2019-05-31 |
| MY200701A (en) | 2024-01-11 |
| EP3548082A1 (en) | 2019-10-09 |
| MA45890B2 (fr) | 2022-10-31 |
| US20210060159A1 (en) | 2021-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| BR112019023754A2 (pt) | anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica. | |
| BR112014008764A2 (pt) | composições para o tratamento de artrite reumatóide e métodos de seu uso | |
| BR112017005517A2 (pt) | anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes | |
| CY1122060T1 (el) | Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων | |
| DOP2016000133A (es) | Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este | |
| WO2014144763A3 (en) | High affinity anti-gd2 antibodies | |
| BR112014018471A2 (pt) | anticorpos anti-ige m1' e métodos para o seu uso | |
| AR080795A1 (es) | Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6) | |
| CL2013002811A1 (es) | Anticuerpo monoclonal aislado que se une a un epitopo del inhibidor de la ruta del factor tisular humano; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar deficiencias o defectos geneticos o adquiridos en la coagulacion. | |
| BR112017026189A2 (pt) | tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4 | |
| BR112017003419A2 (pt) | formulação de anticorpo anti-il-4r-alfa estável | |
| BR112013007314A2 (pt) | anticorpos anti-cd48 e seus usos | |
| BR112015028244A2 (pt) | Imunoconjugado que se liga ao folr1 e seu uso | |
| BR112014008382A2 (pt) | anticorpo especificamente ligando a epítope no domínio sema do c-met | |
| BR112016009047A2 (pt) | Uso de moléculas de ligação à semaforina-4d para tratar transtornos neurodegenerativos | |
| BR112018000212A2 (pt) | uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer | |
| BR112016008010A2 (pt) | uso de moléculas de ligação de semaforina-4d para tratamento de aterosclerose | |
| PH12019501319A1 (en) | Gremlin-1 crystal structure and inhibitory antibody | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| BR112015029300A2 (pt) | Anticorpo biespecífico, composição farmacêutica compreendendo o mesmo, seus usos, usos de um anticorpo anti-ccl2, e um anticorpo anti-loxl2, ou seus fragmentos e kit | |
| BR112016003293A8 (pt) | Anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos | |
| BR112019008279A2 (pt) | uso de beta-catenina como um biomarcador para tratamento de cânceres usando anticorpo anti-dkk-1 | |
| BR112023001061A2 (pt) | Anticorpos antiabeta | |
| BR112014005573A2 (pt) | Anticorpo monoclonal b7-h6 terapeuticamente ativo contra polipeptídeo b7-h6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |